Immunic Reports Completion of Patient Enrollment in P-II CALDOSE-1 Trial of IMU-838 for the Treatment of Ulcerative Colitis

October 28, 2021 Auto Bot Clinical Trials, Immunic, P-II, Pharma, Ulcerative Colitis 0

Shots:

  • The company has completed the enrolment in the P-II CALDOSE-1 trial to evaluate the efficacy & safety of IMU-838 (10/30/45mg, PO) vs PBO in 263 patients with mod. to sev. UC at 100+ sites in 19 countries including the US & EU. The results are expected in Q2’22
  • The 1EPs of the trial include a composite of PRO’s & endoscopy-assessed outcome, following 10wks. of induction treatment
  • IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the DHODH enzyme. In 2020, the company has reported the results from the P-II EMPhASIS trial of IMU-838 in relapsing-remitting MS that achieved both 1EPs & 2EPs with high significance

Click here ­to­ read full press release/ article | Ref: PR Newswire | Image: WFLX

The post Immunic Reports Completion of Patient Enrollment in P-II CALDOSE-1 Trial of IMU-838 for the Treatment of Ulcerative Colitis first appeared on PharmaShots.